In July 2025, Recursion Pharmaceuticals acquired Rallybio’s full stake in their joint venture for developing REV102 and an associated backup molecule for the treatment of hypophosphatasia.

Learn how to use pattern-matching features in your Java programs, including pattern matching with switch statements, when clauses, sealed classes, and a preview of primitive type pattern matching ...

The release introduces the Jakarta Data specification, updates testing frameworks, and aligns with Java 21, the latest long-term support version of Java. The platform now supports Java 17 or higher ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. Quiver AI Summary MIT and Recursion have released Boltz-2 ...

Recursion’s pipeline shuffle follows the company’s acquisition of AI development peer Exscientia late last year.

The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites ...

"Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials," said Andrew Kress, CEO of HealthVerity.

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the resources to bridge the gap, writes Recursion Pharmaceuticals CEO ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor ...